Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1981 8
1982 10
1983 17
1984 24
1985 53
1986 45
1987 130
1988 85
1989 177
1990 134
1991 153
1992 146
1993 163
1994 302
1995 287
1996 256
1997 221
1998 309
1999 219
2000 199
2001 232
2002 184
2003 233
2004 179
2005 260
2006 225
2007 192
2008 144
2009 133
2010 148
2011 132
2012 128
2013 128
2014 117
2015 96
2016 75
2017 58
2018 77
2019 79
2020 59
2021 54
2022 33
2023 38
2024 38
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,705 results

Results by year

Filters applied: . Clear all
Page 1
A randomized clinical trial of topical dexamethasone vs. cyclosporine treatment for oral lichen planus.
Georgaki M, Piperi E, Theofilou VI, Pettas E, Stoufi E, Nikitakis NG. Georgaki M, et al. Med Oral Patol Oral Cir Bucal. 2022 Mar 1;27(2):e113-e124. doi: 10.4317/medoral.25040. Med Oral Patol Oral Cir Bucal. 2022. PMID: 34564686 Free PMC article. Clinical Trial.
The aim of this study was to compare the effectiveness of topical dexamethasone vs. topical cyclosporine in treatment of symptomatic OLP. MATERIAL AND METHODS: Thirty-two patients with biopsy-proven symptomatic OLP were randomly assigned to two therapeutic groups: dexameth …
The aim of this study was to compare the effectiveness of topical dexamethasone vs. topical cyclosporine in treatment of symptomatic …
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
Sall K, Stevenson OD, Mundorf TK, Reis BL. Sall K, et al. Ophthalmology. 2000 Apr;107(4):631-9. doi: 10.1016/s0161-6420(99)00176-1. Ophthalmology. 2000. PMID: 10768324 Clinical Trial.
OBJECTIVE: To compare the efficacy and safety of cyclosporin A ([CsA] 0.05% and 0.1% ophthalmic emulsions) to vehicle in patients with moderate to severe dry eye disease. ...
OBJECTIVE: To compare the efficacy and safety of cyclosporin A ([CsA] 0.05% and 0.1% ophthalmic emulsions) to vehicle in patients wit …
Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with steroid-refractory inflammatory bowel disease.
Allenspach K, Rüfenacht S, Sauter S, Gröne A, Steffan J, Strehlau G, Gaschen F. Allenspach K, et al. J Vet Intern Med. 2006 Mar-Apr;20(2):239-44. doi: 10.1892/0891-6640(2006)20[239:paceoc]2.0.co;2. J Vet Intern Med. 2006. PMID: 16594578 Free article. Clinical Trial.
However, some dogs are refractory to steroid treatment and pose a significant challenge to the veterinarian. Because cyclosporine A (cyA) has been shown to be effective in steroid-resistant IBD in humans, the purpose of this study was to investigate the pharmacokinetics an …
However, some dogs are refractory to steroid treatment and pose a significant challenge to the veterinarian. Because cyclosporine A ( …
Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients.
Smith CL, Hampton EM, Pederson JA, Pennington LR, Bourne DW. Smith CL, et al. Pharmacotherapy. 1994 Jul-Aug;14(4):471-81. Pharmacotherapy. 1994. PMID: 7937285 Clinical Trial.
The effect of the diltiazem-cyclosporine interaction on cyclosporine pharmacokinetics, pharmacodynamics, and pharmacoeconomics was studied in 10 recipients of renal allografts. ...After pharmacokinetic analysis, all patients were followed for 6 months during treatme …
The effect of the diltiazem-cyclosporine interaction on cyclosporine pharmacokinetics, pharmacodynamics, and pharmacoeconomics …
Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria: a clinical and immunological evaluation.
Serhat Inaloz H, Ozturk S, Akcali C, Kirtak N, Tarakcioglu M. Serhat Inaloz H, et al. J Dermatol. 2008 May;35(5):276-82. doi: 10.1111/j.1346-8138.2008.00466.x. J Dermatol. 2008. PMID: 18477227 Clinical Trial.
The present study aimed to evaluate the effectiveness of 2.5 mg/kg/day cyclosporin (CsA) treatment in patients with severe chronic idiopathic urticaria (CIU) and the impact of CsA treatment on several cytokines involved in the etiopathogenesis of CIU. ...
The present study aimed to evaluate the effectiveness of 2.5 mg/kg/day cyclosporin (CsA) treatment in patients with severe chronic id …
A comparative clinical trial of mitomycin C and cyclosporin A in trabeculectomy.
Turaçli E, Gündüz K, Aktan G, Tamer C. Turaçli E, et al. Eur J Ophthalmol. 1996 Oct-Dec;6(4):398-401. doi: 10.1177/112067219600600410. Eur J Ophthalmol. 1996. PMID: 8997582 Clinical Trial.

According to these criteria, IOP was under control in 90% of the mitomycin C treated eyes, 85.7% of cyclosporin A treated eyes and 71.4% of the control eyes. Postoperatively there was a significant decrease in IOP (p < 0.01) and in the number of medications need to cont

…
According to these criteria, IOP was under control in 90% of the mitomycin C treated eyes, 85.7% of cyclosporin A treated eyes and 71 …
A controlled, double-blind, randomized trial of verapamil and cyclosporine in cadaver renal transplant patients.
Pirsch JD, D'Alessandro AM, Roecker EB, Knechtle SJ, Reed A, Sollinger HW, Kalayoglu M, Belzer FO. Pirsch JD, et al. Am J Kidney Dis. 1993 Feb;21(2):189-95. doi: 10.1016/s0272-6386(12)81092-4. Am J Kidney Dis. 1993. PMID: 8430681 Clinical Trial.
Although cyclosporine doses were lower in the placebo group, the mean cyclosporine levels were equivalent in the two groups. ...When compared with placebo, the concomitant use of low-dose verapamil results in lower cyclosporine doses but equivalent cyclosp …
Although cyclosporine doses were lower in the placebo group, the mean cyclosporine levels were equivalent in the two groups. . …
Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
Trull A, Steel L, Sharples L, Stewart S, Parameshwar J, McNeil K, Wallwork J. Trull A, et al. Ther Drug Monit. 1999 Feb;21(1):17-26. doi: 10.1097/00007691-199902000-00004. Ther Drug Monit. 1999. PMID: 10051050 Clinical Trial.
There were no differences in dose-normalized blood cyclosporine concentrations measured predose (C0) or 6 hours postdose between the two groups. ...Despite equivalent C0, those in the Neoral group were consistently exposed to greater blood cyclosporine concentration …
There were no differences in dose-normalized blood cyclosporine concentrations measured predose (C0) or 6 hours postdose between the …
Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects.
Stein CM, Sadeque AJ, Murray JJ, Wandel C, Kim RB, Wood AJ. Stein CM, et al. Clin Pharmacol Ther. 2001 May;69(5):317-23. doi: 10.1067/mcp.2001.115073. Clin Pharmacol Ther. 2001. PMID: 11371999 Clinical Trial.
BACKGROUND: Renal allograft survival is lower in African American patients compared with white patients. Interethnic differences in cyclosporine (INN, ciclosporin) pharmacokinetics in renal transplant recipients have been described but have not been well characteriz …
BACKGROUND: Renal allograft survival is lower in African American patients compared with white patients. Interethnic differences in cyclo …
Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
Morgan RJ Jr, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. Morgan RJ Jr, et al. Cancer Chemother Pharmacol. 2004 Oct;54(4):283-9. doi: 10.1007/s00280-004-0818-x. Epub 2004 Jun 4. Cancer Chemother Pharmacol. 2004. PMID: 15184995 Clinical Trial.
PURPOSE: To determine the response rate to 26-h continuous infusion cyclosporine A (CSA) combined with a fixed dose level of carboplatin (CBDCA) in patients with recurrent ovarian cancer, and to determine the effect of CSA on the pharmacokinetics of CBDCA. ...
PURPOSE: To determine the response rate to 26-h continuous infusion cyclosporine A (CSA) combined with a fixed dose level of carbopla …
5,705 results